SlideShare una empresa de Scribd logo
1 de 16
Descargar para leer sin conexión
Daisuke Yamamoto
Department of Neurology, Shonan Kamakura General Hospital
How to switch
oral antiparkinsonian drugs
to intravenous drugs
in Parkinson disease .
Introduction
Research anticipates that 1 in 1000 people and 1 in 100
elderly develop Parkinson disease (PD). Thus, there are
several cases of acute hospitalizations in patients with PD. In
such a situation, a sudden cessation of antiparkinsonian drugs
could induce neuroleptic malignant syndrome. Therefore,
during disease treatment, it is imperative to manage the
discontinuation of oral antiparkinsonian drugs and switch to
intravenous drugs, which might eventually affect hospitalization.
Through this presentation, I would like suggest a way to
resolve this problem. I hope this presentation is helpful,
especially for medical doctors who cannot consult a specialist.
The occurrence of PD is attributed to the deficiency of dopamine
in the brain. At present, several types of drugs are available for PD
treatment. Among several drugs, L-DOPA supplements dopamine
itself.
Some brand names of L-DOPA are Sinemet, Madpar, or Prolopa.
First, physicians must check whether a patient is taking these drugs
and ascertain their dosages.
The minimum knowledge
of antiparkinsonian drugs <1>.
→ The main antiparkinsonian drug is L-DOPA.
In principle, half the dose of orally administered L-DOPA
should be used for intravenously administering levodopa.
In addition, levodopa should be diluted with normal saline.
The minimum knowledge
of antiparkinsonian drugs <2>
→If a patient cannot take drugs orally,
physicians should switch to
intravenous administration of levodopa.
Dopamine agonists (DAs) constitute one group of antiparkinsonian
drugs; DA is the second most crucial drug after L-DOPA. In case of
difficulty in swallowing, DA administration should be discontinued;
however, a discontinuation might exacerbate the psychotic state,
resulting in dopamine agonist withdrawal syndrome (DAWS).
Thus, an early continuation of DA is desirable to avoid DAWS.
The minimum knowledge of
antiparkinsonian drugs <3>.
→the cessation of dopamine agonist
might pose a risk of developing DAWS.
[If a patient with PD has to discontinue oral intake of L-DOPA in
situations like surgery, 50– 100 mg levodopa is to be
intravenously per 100 mg L-DOPA once in the morning of the
operation day. This can be continued the next day; the dose of
levodopa can be increased according to the symptoms.]
The guidelines on PD treatment by Japanese Society of Neurology
recommend two ways of switching drugs.
<1> Guidelines for the treatment of PD (2011)
[Switch 100-mg L-DOPA to 50–100 mg levodopa, and administer it in
2–3 h . It can also be administered in 1 h.]
The guidelines on PD treatment by Japanese Society of Neurology
recommend two ways of switching drugs.
<2> The guidelines for the treatment of PD (2002)
In the clinical practice, we often chose the latter.
However, there are no clear guidelines to switch drugs.
There exists a more precise approach of
switching from L-DOPA to levodopa.
Precisely, all antiparkinsonian drugs should be changed to their
levodopa equivalent. The website below helps easily detail
Levodopa Equivalent Dose of all drugs.
http://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htm
Ideally, the Levodopa Equivalent Dose of all drugs should be
converted in terms of intravenous levodopa; however, it is not
always recommended to change all antiparkinsonian drugs
because of the differences in administration route.
There might arise a possibility of high levodopa level in the
blood. To avoid this problem, I suggest changing only L-DOPA
to levodopa. Thus, in this manner, please note that a lower
Levodopa Equivalent Dose would be attained.
A patient with PD who was prescribed 300-
mg/day L-DOPA was admitted to the hospital
because of aspiration pneumonia. As a result
of which, he could not take the medicine orally.
In this case ,
300-mg L-DOPA should be changed to
levodopa,
↓
50–100 mg levodopa should be administered
per 100 mg L-DOPA, or
↓
150–300 mg/day levodopa should be
administered.
Prescription
example
Prescription:
levodopa 50 mg
+ normal saline 100 mL
Administer three times a day,
dripping in 2 h
(total levodopa: 150 mg/day)
The purpose of switching therapy
The first objective of switching therapy is to prevent the
development of neuroleptic malignant syndrome.
Another objective is to maintain patients’ activities of daily
living (ADL) and to prevent swallowing dysfunction.
A continuous administration of antiparkinsonian drugs is
needed to avoid these problems.
Continuous intravenous infusion would maintain a constant
blood level of levodopa. Consequently, this therapy would
result in better ADL compared with the therapy involving
divided administration. This therapy can be performed safely,
and I suggest its efficacy in certain cases. Please consider
only one option of the treatment.
Another way
→The continuous
intravenous infusion of levodopa therapy
A patient with PD who was prescribed 300-
mg/day L-DOPA was admitted to the
hospital because of aspiration pneumonia.
He was unable to take medicine orally.
↓
In such a case, switch to continuous
intravenous infusion of levodopa.
Example
Japanese levodopa brand:
Dopaston 1A (20 mg, 20 mL)
Dopaston 6A + normal saline 180 mL
This prescription contains 300 mg
levodopa and 300 mL liquid volume.
Prescription
example Prescription:
Dopaston 6A + normal saline
180 mL
If this is administered at 10 mL/h,
the total amount of levodopa would
be 240 mg/day, which is almost
similar to that in divided
administration. If the patient’s ADL
is inadequate, a dose of 20 or 30
ml/h can also be administered.
Following patient consent,
an NG tube can also be considered to administer drugs.
Of note, sustained-release preparations
cannot be administered from the NG tube.
However, a rotigotine patch can be administered
without interruption.
Irrespective of the clinical department you are working in,
you would face this problem. There is no clear guideline
for switching antiparkinsonian drugs. If you cannot
consult a specialist in your hospital, PD treatment can be
managed by the method proposed in this presentation .
TAKE HOME MESSAGE!
If you have any further questions, or any opinions,
please contact us.
d_yamamoto@shonankamakura.or.jp

Más contenido relacionado

La actualidad más candente

Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine DR ANUP PETARE
 
Headache – practical scenario
Headache – practical scenarioHeadache – practical scenario
Headache – practical scenariowebzforu
 
Migraine headache treatment
Migraine headache treatment Migraine headache treatment
Migraine headache treatment Paul Coelho, MD
 
Migraine pathophysiology, diagnosis and treatments
Migraine pathophysiology, diagnosis and treatmentsMigraine pathophysiology, diagnosis and treatments
Migraine pathophysiology, diagnosis and treatmentsYung-Tsai Chu
 
Migraine and Tension Headache Diagnosis and Treatment Guideline
Migraine and Tension Headache Diagnosis and Treatment GuidelineMigraine and Tension Headache Diagnosis and Treatment Guideline
Migraine and Tension Headache Diagnosis and Treatment GuidelineUtai Sukviwatsirikul
 
Epilepsy presentation
Epilepsy presentationEpilepsy presentation
Epilepsy presentationNeurologyKota
 
Migraine and tension headache diagnosis and treatment guideline
Migraine and tension headache diagnosis and treatment guidelineMigraine and tension headache diagnosis and treatment guideline
Migraine and tension headache diagnosis and treatment guidelineUtai Sukviwatsirikul
 
Migraine - focus on recent advances
Migraine - focus on  recent advancesMigraine - focus on  recent advances
Migraine - focus on recent advancesDr. Samiran Adhikari
 
Via Christi Women's Connection: Migraines
Via Christi Women's Connection: MigrainesVia Christi Women's Connection: Migraines
Via Christi Women's Connection: MigrainesVia Christi Health
 
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)ijtsrd
 
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Laura Kho Sui San, RPh, BCPP
 

La actualidad más candente (20)

Migraine
MigraineMigraine
Migraine
 
cluster headaches
 cluster headaches cluster headaches
cluster headaches
 
Migrane ppt
Migrane pptMigrane ppt
Migrane ppt
 
Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine
 
Headache – practical scenario
Headache – practical scenarioHeadache – practical scenario
Headache – practical scenario
 
Migraine headache treatment
Migraine headache treatment Migraine headache treatment
Migraine headache treatment
 
GP Q&A
GP Q&A GP Q&A
GP Q&A
 
Migraine pathophysiology, diagnosis and treatments
Migraine pathophysiology, diagnosis and treatmentsMigraine pathophysiology, diagnosis and treatments
Migraine pathophysiology, diagnosis and treatments
 
Migraine and Tension Headache Diagnosis and Treatment Guideline
Migraine and Tension Headache Diagnosis and Treatment GuidelineMigraine and Tension Headache Diagnosis and Treatment Guideline
Migraine and Tension Headache Diagnosis and Treatment Guideline
 
Epilepsy presentation
Epilepsy presentationEpilepsy presentation
Epilepsy presentation
 
Migraine guidelines
Migraine guidelinesMigraine guidelines
Migraine guidelines
 
Seroquel
SeroquelSeroquel
Seroquel
 
Schizophrenia (MEDICAL MANAGEMENT
Schizophrenia (MEDICAL MANAGEMENTSchizophrenia (MEDICAL MANAGEMENT
Schizophrenia (MEDICAL MANAGEMENT
 
Migrane
MigraneMigrane
Migrane
 
Migraine and tension headache diagnosis and treatment guideline
Migraine and tension headache diagnosis and treatment guidelineMigraine and tension headache diagnosis and treatment guideline
Migraine and tension headache diagnosis and treatment guideline
 
Migraine - focus on recent advances
Migraine - focus on  recent advancesMigraine - focus on  recent advances
Migraine - focus on recent advances
 
Via Christi Women's Connection: Migraines
Via Christi Women's Connection: MigrainesVia Christi Women's Connection: Migraines
Via Christi Women's Connection: Migraines
 
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)
Conceptual Study of Migraine in Ayurveda (Ardhavbhedaka)
 
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
Breaking Barriers and Improving Treatment Outcomes in Schizophrenia (YMPS-IMU...
 
GP Headache Slides Sept 2016
GP Headache Slides Sept 2016GP Headache Slides Sept 2016
GP Headache Slides Sept 2016
 

Similar a How to switch oral antiparkinsonian drugs to intravenous drugs in Parkinson disease.

Recent advances in the management of Parkinson's Disease (PD)
Recent advances in the  management of Parkinson's Disease (PD)Recent advances in the  management of Parkinson's Disease (PD)
Recent advances in the management of Parkinson's Disease (PD)Sudhir Kumar
 
Adrenergic drugs and there classification
Adrenergic drugs and there  classificationAdrenergic drugs and there  classification
Adrenergic drugs and there classificationNitin Vaidya
 
Management of advanced Parkinson's Disease. dr. Walid Reda Ashour, MD
Management of advanced Parkinson's Disease.   dr. Walid Reda Ashour, MD Management of advanced Parkinson's Disease.   dr. Walid Reda Ashour, MD
Management of advanced Parkinson's Disease. dr. Walid Reda Ashour, MD Walid Ashour
 
Management of early and advanced parkinson disease
Management of early and advanced parkinson diseaseManagement of early and advanced parkinson disease
Management of early and advanced parkinson diseaseNeurologyKota
 
Parkinson disease Walid Reda Ashour Egypt
Parkinson disease  Walid Reda Ashour EgyptParkinson disease  Walid Reda Ashour Egypt
Parkinson disease Walid Reda Ashour EgyptWalid Reda Ashour
 
Antiparkinson's drugs.pptx
Antiparkinson's drugs.pptxAntiparkinson's drugs.pptx
Antiparkinson's drugs.pptxYogeshChauhan95
 
movement.ppt
movement.pptmovement.ppt
movement.pptkireeti8
 
Anti Parkinson Disease | PDF | Pharmacology | Assignment
Anti Parkinson Disease | PDF | Pharmacology | Assignment Anti Parkinson Disease | PDF | Pharmacology | Assignment
Anti Parkinson Disease | PDF | Pharmacology | Assignment MrHotmaster1
 
Dopamine receptor agonists
Dopamine receptor agonistsDopamine receptor agonists
Dopamine receptor agonistsDomina Petric
 
PAKINSONS MX
PAKINSONS MXPAKINSONS MX
PAKINSONS MXArjunNnaa
 
Management of parkinsons disease
Management of parkinsons diseaseManagement of parkinsons disease
Management of parkinsons diseasesadaf89
 
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseNewer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseSudhir Kumar
 
Pharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasePharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasebubuni7386
 
Olanzapine 10mg tablets smpc taj pharmaceuticals
Olanzapine 10mg tablets smpc  taj pharmaceuticalsOlanzapine 10mg tablets smpc  taj pharmaceuticals
Olanzapine 10mg tablets smpc taj pharmaceuticalsTaj Pharma
 
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCRabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCTajPharmaQC
 
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCRabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCTajPharmaQC
 

Similar a How to switch oral antiparkinsonian drugs to intravenous drugs in Parkinson disease. (20)

Recent advances in the management of Parkinson's Disease (PD)
Recent advances in the  management of Parkinson's Disease (PD)Recent advances in the  management of Parkinson's Disease (PD)
Recent advances in the management of Parkinson's Disease (PD)
 
Adrenergic drugs and there classification
Adrenergic drugs and there  classificationAdrenergic drugs and there  classification
Adrenergic drugs and there classification
 
Levodopa ultime 2
Levodopa ultime 2Levodopa ultime 2
Levodopa ultime 2
 
Management of advanced Parkinson's Disease. dr. Walid Reda Ashour, MD
Management of advanced Parkinson's Disease.   dr. Walid Reda Ashour, MD Management of advanced Parkinson's Disease.   dr. Walid Reda Ashour, MD
Management of advanced Parkinson's Disease. dr. Walid Reda Ashour, MD
 
Olazapine
OlazapineOlazapine
Olazapine
 
Management of early and advanced parkinson disease
Management of early and advanced parkinson diseaseManagement of early and advanced parkinson disease
Management of early and advanced parkinson disease
 
Levodopa in Parkinson's disease
Levodopa in Parkinson's diseaseLevodopa in Parkinson's disease
Levodopa in Parkinson's disease
 
Parkinson disease Walid Reda Ashour Egypt
Parkinson disease  Walid Reda Ashour EgyptParkinson disease  Walid Reda Ashour Egypt
Parkinson disease Walid Reda Ashour Egypt
 
Antiparkinson's drugs.pptx
Antiparkinson's drugs.pptxAntiparkinson's drugs.pptx
Antiparkinson's drugs.pptx
 
movement.ppt
movement.pptmovement.ppt
movement.ppt
 
Anti Parkinson Disease | PDF | Pharmacology | Assignment
Anti Parkinson Disease | PDF | Pharmacology | Assignment Anti Parkinson Disease | PDF | Pharmacology | Assignment
Anti Parkinson Disease | PDF | Pharmacology | Assignment
 
Dopamine receptor agonists
Dopamine receptor agonistsDopamine receptor agonists
Dopamine receptor agonists
 
PAKINSONS MX
PAKINSONS MXPAKINSONS MX
PAKINSONS MX
 
Management of parkinsons disease
Management of parkinsons diseaseManagement of parkinsons disease
Management of parkinsons disease
 
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseNewer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
 
Pharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's diseasePharmacotherapy of parkinson's disease
Pharmacotherapy of parkinson's disease
 
Olanzapine 10mg tablets smpc taj pharmaceuticals
Olanzapine 10mg tablets smpc  taj pharmaceuticalsOlanzapine 10mg tablets smpc  taj pharmaceuticals
Olanzapine 10mg tablets smpc taj pharmaceuticals
 
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCRabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
 
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPCRabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
Rabeprazole Sodium 10mg/20mg/40mg Tablets Taj Pharma SmPC
 
Clozapine Therapy.pptx
Clozapine Therapy.pptxClozapine Therapy.pptx
Clozapine Therapy.pptx
 

Más de Daisuke Yamamoto

ジェネラリストのためのてんかん診療のススメ
ジェネラリストのためのてんかん診療のススメジェネラリストのためのてんかん診療のススメ
ジェネラリストのためのてんかん診療のススメDaisuke Yamamoto
 
ERの、そのてんかん発作を評価する。
ERの、そのてんかん発作を評価する。ERの、そのてんかん発作を評価する。
ERの、そのてんかん発作を評価する。Daisuke Yamamoto
 
ラコサミドを中心とした救急病院での入院てんかん治療戦略
ラコサミドを中心とした救急病院での入院てんかん治療戦略ラコサミドを中心とした救急病院での入院てんかん治療戦略
ラコサミドを中心とした救急病院での入院てんかん治療戦略Daisuke Yamamoto
 
ERで遭遇する脳以外の神経疾患入門
ERで遭遇する脳以外の神経疾患入門ERで遭遇する脳以外の神経疾患入門
ERで遭遇する脳以外の神経疾患入門Daisuke Yamamoto
 
脳炎/脳症 ERでできること できないこと
脳炎/脳症 ERでできること できないこと脳炎/脳症 ERでできること できないこと
脳炎/脳症 ERでできること できないことDaisuke Yamamoto
 
良性しびれから、しびれ診療をはじめよう。
良性しびれから、しびれ診療をはじめよう。良性しびれから、しびれ診療をはじめよう。
良性しびれから、しびれ診療をはじめよう。Daisuke Yamamoto
 
認知症についてじぶんのことばで説明しよう。
認知症についてじぶんのことばで説明しよう。認知症についてじぶんのことばで説明しよう。
認知症についてじぶんのことばで説明しよう。Daisuke Yamamoto
 
ERでの非専門医のためのけいれん/てんかん診療ストラテジー
ERでの非専門医のためのけいれん/てんかん診療ストラテジーERでの非専門医のためのけいれん/てんかん診療ストラテジー
ERでの非専門医のためのけいれん/てんかん診療ストラテジーDaisuke Yamamoto
 
About Surfer's myelopathy サーファーズミエロパチー
About Surfer's myelopathy サーファーズミエロパチーAbout Surfer's myelopathy サーファーズミエロパチー
About Surfer's myelopathy サーファーズミエロパチーDaisuke Yamamoto
 
Neurological examination and diagnostic approach for motor disorder
Neurological examination and diagnostic approach for motor disorder Neurological examination and diagnostic approach for motor disorder
Neurological examination and diagnostic approach for motor disorder Daisuke Yamamoto
 
7 Rules for better presentation of brain MRI findings.
7 Rules for better presentation of brain MRI findings.7 Rules for better presentation of brain MRI findings.
7 Rules for better presentation of brain MRI findings.Daisuke Yamamoto
 
パーキンソン病患者さん、ご家族のためのガイドライン解説
パーキンソン病患者さん、ご家族のためのガイドライン解説パーキンソン病患者さん、ご家族のためのガイドライン解説
パーキンソン病患者さん、ご家族のためのガイドライン解説Daisuke Yamamoto
 
Neurological examination (in Japanese)
Neurological examination (in Japanese)Neurological examination (in Japanese)
Neurological examination (in Japanese)Daisuke Yamamoto
 
抗てんかん薬できったてんかん診療入門
抗てんかん薬できったてんかん診療入門抗てんかん薬できったてんかん診療入門
抗てんかん薬できったてんかん診療入門Daisuke Yamamoto
 
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。Daisuke Yamamoto
 
自分でパーキンソン病を疑い、紹介しよう!
自分でパーキンソン病を疑い、紹介しよう!自分でパーキンソン病を疑い、紹介しよう!
自分でパーキンソン病を疑い、紹介しよう!Daisuke Yamamoto
 
treatment of migraine 片頭痛診療、はじめの一歩。
treatment of migraine 片頭痛診療、はじめの一歩。treatment of migraine 片頭痛診療、はじめの一歩。
treatment of migraine 片頭痛診療、はじめの一歩。Daisuke Yamamoto
 
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。Daisuke Yamamoto
 
実践しよう!皮下輸液。
実践しよう!皮下輸液。実践しよう!皮下輸液。
実践しよう!皮下輸液。Daisuke Yamamoto
 
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門Daisuke Yamamoto
 

Más de Daisuke Yamamoto (20)

ジェネラリストのためのてんかん診療のススメ
ジェネラリストのためのてんかん診療のススメジェネラリストのためのてんかん診療のススメ
ジェネラリストのためのてんかん診療のススメ
 
ERの、そのてんかん発作を評価する。
ERの、そのてんかん発作を評価する。ERの、そのてんかん発作を評価する。
ERの、そのてんかん発作を評価する。
 
ラコサミドを中心とした救急病院での入院てんかん治療戦略
ラコサミドを中心とした救急病院での入院てんかん治療戦略ラコサミドを中心とした救急病院での入院てんかん治療戦略
ラコサミドを中心とした救急病院での入院てんかん治療戦略
 
ERで遭遇する脳以外の神経疾患入門
ERで遭遇する脳以外の神経疾患入門ERで遭遇する脳以外の神経疾患入門
ERで遭遇する脳以外の神経疾患入門
 
脳炎/脳症 ERでできること できないこと
脳炎/脳症 ERでできること できないこと脳炎/脳症 ERでできること できないこと
脳炎/脳症 ERでできること できないこと
 
良性しびれから、しびれ診療をはじめよう。
良性しびれから、しびれ診療をはじめよう。良性しびれから、しびれ診療をはじめよう。
良性しびれから、しびれ診療をはじめよう。
 
認知症についてじぶんのことばで説明しよう。
認知症についてじぶんのことばで説明しよう。認知症についてじぶんのことばで説明しよう。
認知症についてじぶんのことばで説明しよう。
 
ERでの非専門医のためのけいれん/てんかん診療ストラテジー
ERでの非専門医のためのけいれん/てんかん診療ストラテジーERでの非専門医のためのけいれん/てんかん診療ストラテジー
ERでの非専門医のためのけいれん/てんかん診療ストラテジー
 
About Surfer's myelopathy サーファーズミエロパチー
About Surfer's myelopathy サーファーズミエロパチーAbout Surfer's myelopathy サーファーズミエロパチー
About Surfer's myelopathy サーファーズミエロパチー
 
Neurological examination and diagnostic approach for motor disorder
Neurological examination and diagnostic approach for motor disorder Neurological examination and diagnostic approach for motor disorder
Neurological examination and diagnostic approach for motor disorder
 
7 Rules for better presentation of brain MRI findings.
7 Rules for better presentation of brain MRI findings.7 Rules for better presentation of brain MRI findings.
7 Rules for better presentation of brain MRI findings.
 
パーキンソン病患者さん、ご家族のためのガイドライン解説
パーキンソン病患者さん、ご家族のためのガイドライン解説パーキンソン病患者さん、ご家族のためのガイドライン解説
パーキンソン病患者さん、ご家族のためのガイドライン解説
 
Neurological examination (in Japanese)
Neurological examination (in Japanese)Neurological examination (in Japanese)
Neurological examination (in Japanese)
 
抗てんかん薬できったてんかん診療入門
抗てんかん薬できったてんかん診療入門抗てんかん薬できったてんかん診療入門
抗てんかん薬できったてんかん診療入門
 
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。
the basic medical treatment of stroke 内科的脳梗塞診療の基本を押さえる。
 
自分でパーキンソン病を疑い、紹介しよう!
自分でパーキンソン病を疑い、紹介しよう!自分でパーキンソン病を疑い、紹介しよう!
自分でパーキンソン病を疑い、紹介しよう!
 
treatment of migraine 片頭痛診療、はじめの一歩。
treatment of migraine 片頭痛診療、はじめの一歩。treatment of migraine 片頭痛診療、はじめの一歩。
treatment of migraine 片頭痛診療、はじめの一歩。
 
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。
Sollid treatment for aseptic meningitis 手堅い、無菌性髄膜炎診療。
 
実践しよう!皮下輸液。
実践しよう!皮下輸液。実践しよう!皮下輸液。
実践しよう!皮下輸液。
 
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門
diagnostic table for stroke まずはここから!脳梗塞の臨床病型診断入門
 

Último

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 

Último (20)

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 

How to switch oral antiparkinsonian drugs to intravenous drugs in Parkinson disease.

  • 1. Daisuke Yamamoto Department of Neurology, Shonan Kamakura General Hospital How to switch oral antiparkinsonian drugs to intravenous drugs in Parkinson disease .
  • 2. Introduction Research anticipates that 1 in 1000 people and 1 in 100 elderly develop Parkinson disease (PD). Thus, there are several cases of acute hospitalizations in patients with PD. In such a situation, a sudden cessation of antiparkinsonian drugs could induce neuroleptic malignant syndrome. Therefore, during disease treatment, it is imperative to manage the discontinuation of oral antiparkinsonian drugs and switch to intravenous drugs, which might eventually affect hospitalization. Through this presentation, I would like suggest a way to resolve this problem. I hope this presentation is helpful, especially for medical doctors who cannot consult a specialist.
  • 3. The occurrence of PD is attributed to the deficiency of dopamine in the brain. At present, several types of drugs are available for PD treatment. Among several drugs, L-DOPA supplements dopamine itself. Some brand names of L-DOPA are Sinemet, Madpar, or Prolopa. First, physicians must check whether a patient is taking these drugs and ascertain their dosages. The minimum knowledge of antiparkinsonian drugs <1>. → The main antiparkinsonian drug is L-DOPA.
  • 4. In principle, half the dose of orally administered L-DOPA should be used for intravenously administering levodopa. In addition, levodopa should be diluted with normal saline. The minimum knowledge of antiparkinsonian drugs <2> →If a patient cannot take drugs orally, physicians should switch to intravenous administration of levodopa.
  • 5. Dopamine agonists (DAs) constitute one group of antiparkinsonian drugs; DA is the second most crucial drug after L-DOPA. In case of difficulty in swallowing, DA administration should be discontinued; however, a discontinuation might exacerbate the psychotic state, resulting in dopamine agonist withdrawal syndrome (DAWS). Thus, an early continuation of DA is desirable to avoid DAWS. The minimum knowledge of antiparkinsonian drugs <3>. →the cessation of dopamine agonist might pose a risk of developing DAWS.
  • 6. [If a patient with PD has to discontinue oral intake of L-DOPA in situations like surgery, 50– 100 mg levodopa is to be intravenously per 100 mg L-DOPA once in the morning of the operation day. This can be continued the next day; the dose of levodopa can be increased according to the symptoms.] The guidelines on PD treatment by Japanese Society of Neurology recommend two ways of switching drugs. <1> Guidelines for the treatment of PD (2011)
  • 7. [Switch 100-mg L-DOPA to 50–100 mg levodopa, and administer it in 2–3 h . It can also be administered in 1 h.] The guidelines on PD treatment by Japanese Society of Neurology recommend two ways of switching drugs. <2> The guidelines for the treatment of PD (2002) In the clinical practice, we often chose the latter. However, there are no clear guidelines to switch drugs.
  • 8. There exists a more precise approach of switching from L-DOPA to levodopa. Precisely, all antiparkinsonian drugs should be changed to their levodopa equivalent. The website below helps easily detail Levodopa Equivalent Dose of all drugs. http://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htm
  • 9. Ideally, the Levodopa Equivalent Dose of all drugs should be converted in terms of intravenous levodopa; however, it is not always recommended to change all antiparkinsonian drugs because of the differences in administration route. There might arise a possibility of high levodopa level in the blood. To avoid this problem, I suggest changing only L-DOPA to levodopa. Thus, in this manner, please note that a lower Levodopa Equivalent Dose would be attained.
  • 10. A patient with PD who was prescribed 300- mg/day L-DOPA was admitted to the hospital because of aspiration pneumonia. As a result of which, he could not take the medicine orally. In this case , 300-mg L-DOPA should be changed to levodopa, ↓ 50–100 mg levodopa should be administered per 100 mg L-DOPA, or ↓ 150–300 mg/day levodopa should be administered. Prescription example Prescription: levodopa 50 mg + normal saline 100 mL Administer three times a day, dripping in 2 h (total levodopa: 150 mg/day)
  • 11. The purpose of switching therapy The first objective of switching therapy is to prevent the development of neuroleptic malignant syndrome. Another objective is to maintain patients’ activities of daily living (ADL) and to prevent swallowing dysfunction. A continuous administration of antiparkinsonian drugs is needed to avoid these problems.
  • 12. Continuous intravenous infusion would maintain a constant blood level of levodopa. Consequently, this therapy would result in better ADL compared with the therapy involving divided administration. This therapy can be performed safely, and I suggest its efficacy in certain cases. Please consider only one option of the treatment. Another way →The continuous intravenous infusion of levodopa therapy
  • 13. A patient with PD who was prescribed 300- mg/day L-DOPA was admitted to the hospital because of aspiration pneumonia. He was unable to take medicine orally. ↓ In such a case, switch to continuous intravenous infusion of levodopa. Example Japanese levodopa brand: Dopaston 1A (20 mg, 20 mL) Dopaston 6A + normal saline 180 mL This prescription contains 300 mg levodopa and 300 mL liquid volume. Prescription example Prescription: Dopaston 6A + normal saline 180 mL If this is administered at 10 mL/h, the total amount of levodopa would be 240 mg/day, which is almost similar to that in divided administration. If the patient’s ADL is inadequate, a dose of 20 or 30 ml/h can also be administered.
  • 14. Following patient consent, an NG tube can also be considered to administer drugs. Of note, sustained-release preparations cannot be administered from the NG tube. However, a rotigotine patch can be administered without interruption.
  • 15. Irrespective of the clinical department you are working in, you would face this problem. There is no clear guideline for switching antiparkinsonian drugs. If you cannot consult a specialist in your hospital, PD treatment can be managed by the method proposed in this presentation . TAKE HOME MESSAGE!
  • 16. If you have any further questions, or any opinions, please contact us. d_yamamoto@shonankamakura.or.jp